Showing 7351-7360 of 8582 results for "".
- Steroids, Steroid/Vitamin D Combo Best Bets for Scalp Psoriasishttps://practicaldermatology.com/news/steroids-steroidvitamin-d-combo-best-bets-for-scalp-psoriasis/2458680/Steroids and the two-compound combination of a steroid plus vitamin D are the most effective treatments for scalp psoriasis, according to a new Cochrane review. Statistically, the combination product
- Pioneer in Laser Development to Give Keynote at ASLMS 2016https://practicaldermatology.com/news/pioneer-in-laser-development-to-give-keynote-at-aslms-2016/2458682/Robert Afzal, PhD, a leading expert in high power fiber laser development, will deliver the keynote address at ASLMS 2016, the Annual Conference of the American Society for Laser Medicine & Surgery, Inc. (ASLMS), to be held in Boston, Massachusetts March 30 – April 2, 2016. Dr. Afzal wi
- WHO: Improved Access to Psoriasis Treatments Neededhttps://practicaldermatology.com/news/who-improved-access-to-psoriasis-treatments-needed/2458685/Key stakeholders including policy makers, physicians and patients must come together to turn the corner on psoriasis, according to the World Health Organization’s (WHO) new Globa
- Dr. Bruce Strober Appointed Chair of Dermatology at UConn Healthhttps://practicaldermatology.com/news/dr-bruce-strober-appointed-chair-of-dermatology-at-uconn-health/2458694/Bruce E. Strober, MD, PhD has been appointed chair of the Department of Dermatology at UConn Health and professor of dermatology at UConn School of Medicine. Dr. Strober has served as the interim chair of the Department of Dermatology since 2015 and vice chair since joining UConn Health in 2011.
- New AAD Acne Guidelines Call for Combination Therapyhttps://practicaldermatology.com/news/new-aad-acne-guidelines-call-for-combination-therapy/2458695/Combination therapy is the way forward for treating moderate-to-mild acne, according to new guidelines from The American Academy of Dermatology. For example, antibiotics should be used with topical acne therapy, and patients should continue using topical treatments to manage their c
- Hidradenitis Suppurativa Ups Risk of Adverse CV Eventshttps://practicaldermatology.com/news/hidradenitis-suppurativa-ups-risk-of-adverse-cv-events/2458696/Hidradenitis suppurativa (HS) may increase risk for adverse cardiovascular outcomes, a new study suggests. HS has been associated with cardiovascular risk factors, such as smoking and obesity, but the risk of cardiovascular disease in patients with HS was unknown. The new study
- Sturge-Weber Foundation to Host Dermatology Roundtablehttps://practicaldermatology.com/news/sturge-weber-foundation-to-host-dermatology-roundtable/2458697/The Sturge-Weber Foundation (SWF) is holding a Dermatology Discussion Roundtable meeting on March 5, 2016, at the Marriott Marquis in Washington, DC. Attendees of the American Academy of Dermatology (AAD) conference are invited to attend this breakfast meeting from 7:30 a.m. to 9:30 a.m. in the J
- Caladrius Biosciences Licenses Dermatology Cell Technology to AiVita Biomedicalhttps://practicaldermatology.com/news/caladrius-biosciences-licenses-dermatology-cell-technology-to-aivita-biomedical/2458698/Caladrius Biosciences, Inc., has licensed exclusive global rights to its cell-derived dermatological technology for topical skin applications to AiVita Biomedical, Inc. The company says this transaction supports its strategy to monetize non-core assets. AiVita, a biotechnology company, wa
- Cipher's Sitavig Accepted for Review by Health Canadahttps://practicaldermatology.com/news/ciphers-sitavig-accepted-for-review-by-health-canada/2458701/Cipher Pharmaceuticals Inc.’s New Drug Submission for Sitavig has been accepted for review by Health Canada. Sitavig (acyclovir mucoadhesive buccal tablets) is proposed for the treatment of recurrent herpes labialis in adults. In the United States, Sitavig® is approve
- FDA Accepts Allergan's sNDA for TEFLARO Use in Childrenhttps://practicaldermatology.com/news/fda-accepts-allergans-snda-for-teflaro-use-in-children/2458700/The U.S. Food and Drug Administration (FDA) has accepted Allergan’s supplemental New Drug Application (sNDA) for IV antibacterial TEFLARO® (ceftaroline fosamil). If approved, this filing will expand the label of TEFLARO beyond adults to include children two months of age a